Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra for CRS and Neurotoxicity Prevention in B-Cell Lymphoma
NCT04359784Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Dec 2021
- Primary completion
- Oct 2024
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of anakinra in cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), sponsored by Fred Hutchinson Cancer Center. Started Dec 2021; status: completed.
02
Drugs
anakinra
03
Conditions
cytokine release syndrome (CRS)immune effector cell-associated neurotoxicity syndrome (ICANS)
Beyond the preview
Go deeper on NCT04359784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04359784.